Comparative Efficacy of Inhaled and Intravenous Corticosteroids in Managing COVID-19-Related Acute Respiratory Distress Syndrome
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Gibson, P.G.; Qin, L.; Puah, S.H. COVID-19 acute respiratory distress syndrome (ARDS): Clinical features and differences from typical pre-COVID-19 ARDS. Med. J. Aust. 2020, 213, 54–56.e1. [Google Scholar] [CrossRef]
- Montenegro, F.; Unigarro, L.; Paredes, G.; Moya, T.; Romero, A.; Torres, L.; López, J.C.; González, F.E.J.; Del Pozo, G.; Lopez-Cortes, A.L. Acute respiratory distress syndrome (ARDS) caused by the novel coronavirus disease (COVID-19): A practical comprehensive literature review. Expert Rev. Respir. Med. 2021, 15, 183–195. [Google Scholar] [CrossRef]
- Li, C.; He, Q.; Qian, H.; Liu, J.; Medicine, T. Overview of the pathogenesis of COVID-19. Exp. Ther. Med. 2021, 22, 1011. [Google Scholar] [CrossRef]
- Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [Google Scholar] [CrossRef]
- Poon, L.C.; Yang, H.; Kapur, A.; Melamed, N.; Dao, B.; Divakar, H.; McIntyre, H.D.; Kihara, A.B.; Ayres-de-Campos, D.; Ferrazzi, E.M.; et al. Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet. 2020, 149, 273–286. [Google Scholar] [CrossRef]
- Kryger, M.; Goldstein, C.A. COVID-19 and sleep. Age 2022, 700, 600. [Google Scholar]
- Sharma, A.; Tiwari, S.; Deb, M.K.; Marty, J.L. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies. Int. J. Antimicrob. Agents 2020, 56, 106054. [Google Scholar] [CrossRef]
- Wiersinga, W.J.; Rhodes, A.; Cheng, A.C.; Peacock, S.J.; Prescott, H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA 2020, 324, 782–793. [Google Scholar] [CrossRef]
- Fatima, S.A.; Asif, M.; Khan, K.A.; Siddique, N.; Khan, A.Z. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe COVID-19 disease. Ann. Med. Surg. 2020, 60, 413–416. [Google Scholar] [CrossRef]
- Patel, V.K.; Shirbhate, E.; Patel, P.; Veerasamy, R.; Sharma, P.C.; Rajak, H. Corticosteroids for treatment of COVID-19: Effect, evidence, expectation and extent. Beni Suef Univ. J. Basic Appl. Sci. 2021, 10, 78. [Google Scholar] [CrossRef]
- Sen, P.; Majumdar, U.; Zein, J.; Hatipoğlu, U.; Attaway, A.H. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic’s COVID-19 registry. PLoS ONE 2021, 16, e0252576. [Google Scholar] [CrossRef] [PubMed]
- Hu, B.; Guo, H.; Zhou, P.; Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021, 19, 141–154. [Google Scholar] [CrossRef] [PubMed]
- Polidoro, R.B.; Hagan, R.S.; de Santis Santiago, R.; Schmidt, N.W. Overview: Systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Front. Immunol. 2020, 11, 1626. [Google Scholar] [CrossRef] [PubMed]
- Cheon, S.Y.; Koo, B.-N. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2. Int. J. Mol. Sci. 2021, 22, 7914. [Google Scholar] [CrossRef] [PubMed]
- Abdelrahim, M.E.; Plant, P.; Chrystyn, H. In-vitro characterisation of the nebulised dose during non-invasive ventilation. J. Pharm. Pharmacol. 2010, 62, 966–972. [Google Scholar] [CrossRef] [PubMed]
- Tale, S.; Ghosh, S.; Meitei, S.P.; Kolli, M.; Garbhapu, A.K.; Pudi, S. Post-COVID-19 pneumonia pulmonary fibrosis. Qjm Int. J. Med. 2020, 113, 837–838. [Google Scholar] [CrossRef] [PubMed]
- von der Thüsen, J.; van der Eerden, M. Histopathology and genetic susceptibility in COVID-19 pneumonia. Eur. J. Clin. Investig. 2020, 50, e13259. [Google Scholar] [CrossRef] [PubMed]
- Lu, S.; Zhou, Q.; Huang, L.; Shi, Q.; Zhao, S.; Wang, Z.; Li, W.; Tang, Y.; Ma, Y.; Luo, X. Effectiveness and safety of glucocorticoids to treat COVID-19: A rapid review and meta-analysis. Ann. Transl. Med. 2020, 8, 627. [Google Scholar] [CrossRef] [PubMed]
- Jin, Y.; Cai, L.; Cheng, Z.; Cheng, H.; Deng, T.; Fan, Y.; Fang, C.; Huang, D.; Huang, L.; Huang, Q. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil. Med. Res. 2020, 7, 4. [Google Scholar] [CrossRef]
- Williams, D.M. Clinical pharmacology of corticosteroids. Respir. Care 2018, 63, 655–670. [Google Scholar] [CrossRef]
- Hasan, S.S.; Capstick, T.; Ahmed, R.; Kow, C.S.; Mazhar, F.; Merchant, H.A.; Zaidi, S.T.R. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: A systematic review and meta-analysis. Expert Rev. Respir. Med. 2020, 14, 1149–1163. [Google Scholar] [CrossRef] [PubMed]
- Tan, L.Y.; Komarasamy, T.V.; Balasubramaniam, V.R. Hyperinflammatory immune response and COVID-19: A double edged sword. Front. Immunol. 2021, 12, 742941. [Google Scholar] [CrossRef] [PubMed]
- Petersen, M.W.; Meyhoff, T.S.; Helleberg, M.; Kjær, M.B.N.; Granholm, A.; Hjortsø, C.J.S.; Jensen, T.S.; Møller, M.H.; Hjortrup, P.B.; Wetterslev, M. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial—Protocol and statistical analysis plan. Acta Anaesthesiol. Scand. 2020, 64, 1365–1375. [Google Scholar] [CrossRef] [PubMed]
- Chaudhuri, D.; Sasaki, K.; Karkar, A.; Sharif, S.; Lewis, K.; Mammen, M.J.; Alexander, P.; Ye, Z.; Lozano, L.E.C.; Munch, M.W. Corticosteroids in COVID-19 and non-COVID-19 ARDS: A systematic review and meta-analysis. Intensive Care Med. 2021, 47, 521–537. [Google Scholar] [CrossRef] [PubMed]
- Ranjbar, K.; Moghadami, M.; Mirahmadizadeh, A.; Fallahi, M.J.; Khaloo, V.; Shahriarirad, R.; Erfani, A.; Khodamoradi, Z.; Gholampoor Saadi, M.H. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: A triple-blinded randomized controlled trial. BMC Infect. Dis. 2021, 21, 337. [Google Scholar] [CrossRef] [PubMed]
- Maia, R.; Melo, L.; Mendes, J.J.; Freitas, P.T. Corticosteroids in COVID-19: A double-edged sword—A retrospective study. Med Intensiv. 2022, 46, 229–231. [Google Scholar] [CrossRef] [PubMed]
- Bahl, A.; Johnson, S.; Chen, N.-W. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Intern. Emerg. Med. 2021, 16, 1593–1603. [Google Scholar] [CrossRef] [PubMed]
- Muñoz-Martínez, S.; Sapena, V.; Forner, A.; Nault, J.-C.; Sapisochin, G.; Rimassa, L.; Sangro, B.; Bruix, J.; Sanduzzi-Zamparelli, M.; Hołówko, W. Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Rep. 2021, 3, 100260. [Google Scholar] [CrossRef]
- Marjot, T.; Moon, A.M.; Cook, J.A.; Abd-Elsalam, S.; Aloman, C.; Armstrong, M.J.; Pose, E.; Brenner, E.J.; Cargill, T.; Catana, M.-A. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J. Hepatol. 2021, 74, 567–577. [Google Scholar] [CrossRef]
- Iavarone, M.; D’Ambrosio, R.; Soria, A.; Triolo, M.; Pugliese, N.; Del Poggio, P.; Perricone, G.; Massironi, S.; Spinetti, A.; Buscarini, E. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J. Hepatol. 2020, 73, 1063–1071. [Google Scholar] [CrossRef]
- Morgan, P.; Arnold, S.J.; Hsiao, N.-W.; Shu, C.-W. A Closer Look at Dexamethasone and the SARS-CoV-2-Induced Cytokine Storm: In Silico Insights of the First Life-Saving COVID-19 Drug. Antibiotics 2021, 10, 1507. [Google Scholar] [CrossRef] [PubMed]
- Villar, J.; Ferrando, C.; Martínez, D.; Ambrós, A.; Muñoz, T.; Soler, J.A.; Aguilar, G.; Alba, F.; González-Higueras, E.; Conesa, L.A. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir. Med. 2020, 8, 267–276. [Google Scholar] [CrossRef] [PubMed]
- Fei, Q.; Bentley, I.; Ghadiali, S.N.; Englert, J.A. Pulmonary drug delivery for acute respiratory distress syndrome. Pulm. Pharmacol. Ther. 2023, 79, 102196. [Google Scholar] [CrossRef] [PubMed]
- Zeitlinger, M.; Idzko, M. Inhaled budesonide for early treatment of COVID-19. Lancet Respir. Med. 2021, 9, e59. [Google Scholar] [CrossRef] [PubMed]
- Mohamed, H.S.; Meguid, M.M.A. Effect of nebulized budesonide on respiratory mechanics and oxygenation in acute lung injury/acute respiratory distress syndrome: Randomized controlled study. Saudi J. Anaesth. 2017, 11, 9–14. [Google Scholar] [CrossRef] [PubMed]
- Ding, Z.; Li, X.; Lu, Y.; Rong, G.; Yang, R.; Zhang, R.; Wang, G.; Wei, X.; Ye, Y.; Qian, Z. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. Respir. Med. 2016, 121, 39–47. [Google Scholar] [CrossRef] [PubMed]
- Choi, K.J.; Jung, S.K.; Kim, K.C.; Kim, E.J. Methylprednisolone pulse therapy for critically ill patients with COVID-19: A cohort study. Acute Crit. Care 2023, 38, 57–67. [Google Scholar] [CrossRef] [PubMed]
- Jantz, M.A.; Sahn, S.A. Corticosteroids in acute respiratory failure. Am. J. Respir. Crit. Care Med. 1999, 160, 1079–1100. [Google Scholar] [CrossRef] [PubMed]
- Patel, C.; Parmar, K.; Patel, D.; Patel, S.; Sheth, D.; Beladiya, J.V. Effect of corticosteroid therapy on mortality in COVID-19 patients—A systematic review and meta-analysis. Rev. Med. Virol. 2022, 32, e2386. [Google Scholar] [CrossRef]
- Ho, K.S.; Narasimhan, B.; Difabrizio, L.; Rogers, L.; Bose, S.; Li, L.; Chen, R.; Sheehan, J.; El-Halabi, M.A.; Sarosky, K. Impact of corticosteroids in hospitalised COVID-19 patients. BMJ Open Respir. Res. 2021, 8, e000766. [Google Scholar] [CrossRef]
- Fadel, R.; Morrison, A.R.; Vahia, A.; Smith, Z.R.; Chaudhry, Z.; Bhargava, P.; Miller, J.; Kenney, R.M.; Alangaden, G.; Ramesh, M.S. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin. Infect. Dis. 2020, 71, 2114–2120. [Google Scholar] [CrossRef]
- Majmundar, M.; Kansara, T.; Lenik, J.M.; Park, H.; Ghosh, K.; Doshi, R.; Shah, P.; Kumar, A.; Amin, H.; Chaudhari, S. Efficacy of corticosteroids in non-intensive care unit patients with COVID-19 pneumonia from the New York Metropolitan region. PLoS ONE 2020, 15, e0238827. [Google Scholar] [CrossRef]
- Angus, D.C.; Derde, L.; Al-Beidh, F.; Annane, D.; Arabi, Y.; Beane, A.; van Bentum-Puijk, W.; Berry, L.; Bhimani, Z.; Bonten, M. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA 2020, 324, 1317–1329. [Google Scholar]
- Rubio, J.L.C.; Del Castillo, J.d.D.L.; de la Hera Fernández, J.; Arrabal, E.G.; Ruiz, M.C.; Centeno, N.O. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection. Med. Clín. 2020, 155, 159–161. [Google Scholar]
- Wang, Y.; Jiang, W.; He, Q.; Wang, C.; Wang, B.; Zhou, P.; Dong, N.; Tong, Q. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct. Target. Ther. 2020, 5, 57. [Google Scholar] [CrossRef]
- Jeronimo, C.M.P.; Farias, M.E.L.; Val, F.F.A.; Sampaio, V.S.; Alexandre, M.A.A.; Melo, G.C.; Safe, I.P.; Borba, M.G.S.; Abreu-Netto, R.L.; Maciel, A.B.S. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase IIb, placebo-controlled trial. Clin. Infect. Dis. 2020, 72, e373–e381. [Google Scholar] [CrossRef]
- Yasir, M.; Goyal, A.; Sonthalia, S. Corticosteroid Adverse Effects. In StatPearls; StatPearls Publishing LLC.: Treasure Island, FL, USA, 2024. [Google Scholar]
- Song, M.; Liu, Y.; Lu, Z.; Luo, H.; Peng, H.; Chen, P. Prognostic factors for ARDS: Clinical, physiological and atypical immunodeficiency. BMC Pulm. Med. 2020, 20, 102. [Google Scholar] [CrossRef] [PubMed]
- Xu, B.; Ge, Y.; Lu, Y.; Chen, Q.; Zhang, H. Risk factors and prognosis of acute respiratory distress syndrome following abdominal surgery. Exp. Ther. Med. 2019, 17, 159–164. [Google Scholar] [CrossRef]
- Fernando, S.M.; Ferreyro, B.L.; Urner, M.; Munshi, L.; Fan, E. Diagnosis and management of acute respiratory distress syndrome. Can. Med. Assoc. J. 2021, 193, E761–E768. [Google Scholar] [CrossRef]
- Palakshappa, J.A.; Krall, J.T.; Belfield, L.T.; Files, D.C. Long-term outcomes in acute respiratory distress syndrome: Epidemiology, mechanisms, and patient evaluation. Crit. Care Clin. 2021, 37, 895–911. [Google Scholar] [CrossRef]
- Chiumello, D.; Coppola, S.; Froio, S.; Gotti, M. What’s next after ARDS: Long-term outcomes. Respir. Care 2016, 61, 689–699. [Google Scholar] [CrossRef] [PubMed]
Parameter | (I) Group | (J) Group | p-Value | Parameter | (I) Group | (J) Group | p-Value |
---|---|---|---|---|---|---|---|
Day 1 vs. Day 6 | Day 1 vs. Day 11 | ||||||
D6-D1-CRP | Dexamethasone | budesonide | 0.012 | D11-D1-CRP | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.346 | Methylprednisolone | 0.394 | ||||
Budesonide | Methylprednisolone | 0.346 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-Ferritin | Dexamethasone | budesonide | 1.000 | D11-D1-Ferritin | Dexamethasone | budesonide | 0.696 |
Methylprednisolone | 0.374 | Methylprednisolone | 0.268 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-Lympho | Dexamethasone | budesonide | 1.000 | D11-D1-Lympho | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.910 | Methylprednisolone | 1.000 | ||||
Budesonide | Methylprednisolone | 0.298 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-TLC | Dexamethasone | budesonide | 1.000 | D11-D1-TLC | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.101 | Methylprednisolone | 0.075 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-PLTs | Dexamethasone | budesonide | 0.087 | D11-D1-PLTs | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.058 | Methylprednisolone | 0.042 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 0.808 | ||
D6-D1-Hb | Dexamethasone | budesonide | 0.613 | D11-D1-Hb | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.001 | Methylprednisolone | 0.081 | ||||
Budesonide | Methylprednisolone | 0.199 | Budesonide | Methylprednisolone | 0.705 | ||
D6-D1-Urea | Dexamethasone | budesonide | 1.000 | D11-D1-Urea | Dexamethasone | budesonide | 0.809 |
Methylprednisolone | 1.000 | Methylprednisolone | 1.000 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-s.K | Dexamethasone | budesonide | 0.615 | D11-D1-s.K | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.007 | Methylprednisolone | 0.167 | ||||
budesonide | Methylprednisolone | 0.562 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-s.Creat | Dexamethasone | budesonide | 1.000 | D11-D1-s.Creat | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.549 | Methylprednisolone | 0.097 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 0.261 | ||
D6-D1-s.Na | Dexamethasone | budesonide | 0.379 | D11-D1-s.Na | Dexamethasone | budesonide | 0.906 |
Methylprednisolone | 0.098 | Methylprednisolone | 1.000 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 0.523 | ||
D6-D1-SGPT | Dexamethasone | budesonide | 1.000 | D11-D1-SGPT | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.873 | Methylprednisolone | 1.000 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-SGOT | Dexamethasone | budesonide | 0.715 | D11-D1-SGOT | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.295 | Methylprednisolone | 0.412 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-Uric acid | Dexamethasone | budesonide | 1.000 | D11-D1-Uric acid | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 1.000 | Methylprednisolone | 0.131 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 0.284 | ||
D6-D1-ESR | Dexamethasone | budesonide | 1.000 | D11-D1-ESR | Dexamethasone | budesonide | 0.961 |
Methylprednisolone | 0.616 | Methylprednisolone | 0.799 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-INR | Dexamethasone | budesonide | 0.921 | D11-D1-INR | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 1.000 | Methylprednisolone | 1.000 | ||||
Budesonide | Methylprednisolone | 1.000 | budesonide | Methylprednisolone | 1.000 | ||
D6-D1-O2 Sat without flow | Dexamethasone | budesonide | 0.700 | D11-D1-O2 Sat without flow | Dexamethasone | budesonide | 1.000 |
Methylprednisolone | 0.146 | Methylprednisolone | 0.337 | ||||
Budesonide | Methylprednisolone | 1.000 | Budesonide | Methylprednisolone | 1.000 | ||
D6-D1-O2 Sat with flow | Dexamethasone | budesonide | 0.000 | D11-D1-O2 Sat with flow | Dexamethasone | budesonide | 0.000 |
Methylprednisolone | 1.000 | Methylprednisolone | 1.000 | ||||
Budesonide | Methylprednisolone | 0.000 | Budesonide | Methylprednisolone | 0.000 |
Parameter | (I) Group | (J) Group | p-Value |
---|---|---|---|
Day 1 vs. Day 6 | |||
D11-D6-CRP | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.180 | ||
Budesonide | Methylprednisolone | 0.278 | |
D11-D6-Ferritin | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.433 | ||
Budesonide | Methylprednisolone | 1.000 | |
D11-D6-Lympho | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.070 | ||
Budesonide | Methylprednisolone | 0.795 | |
D11-D6-TLC | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 1.000 | ||
Budesonide | Methylprednisolone | 1.000 | |
D11-D6-PLTs | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 1.000 | ||
Budesonide | Methylprednisolone | 1.000 | |
D11-D6-Hb | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 1.000 | ||
Budesonide | Methylprednisolone | 1.000 | |
D11-D6-Urea | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.049 | ||
Budesonide | Methylprednisolone | 1.000 | |
D11-D6-s.K | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.794 | ||
Budesonide | Methylprednisolone | 1.000 | |
D11-D6-s.Creat | Dexamethasone | Budesonide | 0.699 |
Methylprednisolone | 1.000 | ||
Budesonide | Methylprednisolone | 0.353 | |
D11-D6-s.Na | Dexamethasone | Budesonide | 0.978 |
Methylprednisolone | 0.000 | ||
Budesonide | Methylprednisolone | 0.008 | |
D11-D6-SGPT | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.051 | ||
Pulmicort | Methylprednisolone | 0.149 | |
D11-D6-SGOT | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.484 | ||
Budesonide | Methylprednisolone | 1.000 | |
D11-D6-Uric acid | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.003 | ||
Budesonide | Methylprednisolone | 0.175 | |
D11-D6-ESR | Dexamethasone | Budesonide | 0.242 |
Methylprednisolone | 0.941 | ||
Budesonide | Methylprednisolone | 0.644 | |
D11-D6-INR | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.022 | ||
Budesonide | Methylprednisolone | 0.075 | |
D11-D6-O2 Sat without flow | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.283 | ||
Budesonide | Methylprednisolone | 1.000 | |
D6-D1-O2 Sat with flow | Dexamethasone | Budesonide | 0.000 |
Methylprednisolone | 1.000 | ||
Budesonide | Methylprednisolone | 0.000 | |
Hospital Stay | Dexamethasone | Budesonide | 1.000 |
Methylprednisolone | 0.948 | ||
Budesonide | Methylprednisolone | 1.000 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Abdelkader, A.A.; Alsfouk, B.A.; Saleh, A.; Abdelrahim, M.E.A.; Saeed, H. Comparative Efficacy of Inhaled and Intravenous Corticosteroids in Managing COVID-19-Related Acute Respiratory Distress Syndrome. Pharmaceutics 2024, 16, 952. https://doi.org/10.3390/pharmaceutics16070952
Abdelkader AA, Alsfouk BA, Saleh A, Abdelrahim MEA, Saeed H. Comparative Efficacy of Inhaled and Intravenous Corticosteroids in Managing COVID-19-Related Acute Respiratory Distress Syndrome. Pharmaceutics. 2024; 16(7):952. https://doi.org/10.3390/pharmaceutics16070952
Chicago/Turabian StyleAbdelkader, Ahmed A., Bshra A. Alsfouk, Asmaa Saleh, Mohamed E. A. Abdelrahim, and Haitham Saeed. 2024. "Comparative Efficacy of Inhaled and Intravenous Corticosteroids in Managing COVID-19-Related Acute Respiratory Distress Syndrome" Pharmaceutics 16, no. 7: 952. https://doi.org/10.3390/pharmaceutics16070952
APA StyleAbdelkader, A. A., Alsfouk, B. A., Saleh, A., Abdelrahim, M. E. A., & Saeed, H. (2024). Comparative Efficacy of Inhaled and Intravenous Corticosteroids in Managing COVID-19-Related Acute Respiratory Distress Syndrome. Pharmaceutics, 16(7), 952. https://doi.org/10.3390/pharmaceutics16070952